cyrilzakka/clinical-trials huggingface dataset:
Utility of Disconnection Technique for One Lung Ventilation

Lung isolation technique is useful for lung or heart surgeries for better visualization. Double lumen endobronchial tube and bronchial blocker are available for lung isolation. Adding disconnection technique before lung isolation is helpful to accelerate the lung deflation. However, the utility of disconnection technique has never been evaluated in comparison of double lumen tube and bronchial blocker. Therefore, the utility of disconnection technique in two different lung isolation technique, double lumen tube and bronchial blocker will be evaluated


Eligibility Criteria:
Inclusion Criteria:

* patients scheduled for wedge resection for pneumothorax, unilateral
* ASA class I, II

Exclusion Criteria:

* know lung disease
* any kind of lung abnormality on preoperative chest x-ray
* coronary artery occlusive disease
* cerebrovascular disease
* pregnancy
* unable to understand the informed consent form
Penicillin Allergy Delabeling Among Surgical Patients

Penicillin allergy testing among surgical patients


Eligibility Criteria:
Inclusion Criteria:

* surgical patients with reported penicillin allergy

Exclusion Criteria:

* missing consent
Study of Inhaled RNS60 in Combination With Budesonide to Treat Mild to Moderate Asthma

The purpose of this study is to determine whether RNS60, in combination with budesonide, is safe in mild to moderate asthmatics when taken by nebulization over a 28-day period, compared to a 28-day control period.


Eligibility Criteria:
Inclusion Criteria:

* Male or female non-smokers, aged between 18 and 65 years.
* Clinical diagnosis of mild to moderate asthma meeting NHLBI 2007 guidelines as outlined in Appendix A.
* Subjects who have a currently prescribed inhaled corticosteroid medication to treat asthma, alone or in combination with other medications, with usage of 1 month (≥ 95% compliance) or more on the inhaled corticosteroid treatment.
* Normal 12-lead ECG at Screening.
* Normal single view chest x-ray at Screening.
* Men and women of reproductive potential who commit to use adequate contraception during the study and for 1 month following the last day of treatment (Day 57).
* Women of childbearing potential who have a negative pregnancy test (serum HCG) at the time of study entry, and again on Day 22.
* Subjects, or their legal guardians, must be capable of understanding the purpose and risks of the study and provide written, voluntary, informed consent.

Exclusion Criteria:

* Chronic or acute disease that might interfere with the evaluation of RNS60.
* Pregnancy, intent to become pregnant, or breastfeeding.
* Current or prior malignancies (excluding non-melanoma skin carcinoma or in situ carcinoma of the cervix that has been adequately treated).
* Positive viral serology test for Human Immunodeficiency Virus (HIV-1), HBsAG and Hepatitis C antibody.
* Positive urine drug screen (UDS) for drugs of abuse including alcohol and cotinine at the time of study entry and again on Day 22.
* Infections that require intravenous antibiotic therapy.
* Significant organ dysfunction, including cardiac, renal, liver, central nervous system, pulmonary, vascular, gastrointestinal, endocrine, or metabolic (e.g., creatinine ≥ 1.6 mg/dL; ALT or AST ≥ 1.5x the upper limit of normal), history of myocardial infarction, congestive heart failure, or arrhythmias within 6 months prior to study entry.
* Treatment with a humanized or chimeric antibody therapy within 4 weeks prior to study entry.
* Treatment with any investigational drugs, therapies, or medical devices within 4 weeks prior to study entry.
* Any use of antidepressants or other psychiatric medicine within 4 weeks prior to study entry and/or during the study treatment period.
* Use of any over-the-counter asthma treatments, including Primatene Mist, during the 8-week active study period.
Efficiency of Different Modes of Universal Adhesive

The purpose of this study is to evaluate and compare the clinical performance of a Universal adhesive's different application modes.

Class 2 composite restorations will be placed using a bulk-fill composite resin restorative on two posterior teeth with proximal caries, in a split mouth design. 25 patients will be included in the study. The teeth will be randomized into two groups according to the application mode of universal adhesive material.

Group 1: the universal adhesive will be used in etch-and-rinse mode Group 2: the universal adhesive will be used in self-etch mode. The US Public Health Service criteria (secondary caries, anatomical form, surface roughness, marginal integrity, marginal discoloration and retention) will be used for clinical evaluation of atraumatic resin restorations. The restorations will be evaluated at baseline and 6th, 12th, 18th, 24th months. Intra-oral photos will be taken directly after treatment and at control appointments to evaluate discoloration and seconder caries under magnification.

The data will be analysed statistically using Fisher's Exact Test; and the Kaplan-Meier and Wilcoxon method will be used to estimate survival percentages.

Eligibility Criteria:
Inclusion Criteria:

* a need for at least two but not more than four posterior tooth-colored restorations
* the presence of teeth to be restored in occlusion
* teeth that were symptomless and vital
* a normal periodontal status
* a good likelihood of recall availability.

Exclusion Criteria:

* partly erupted teeth
* absence of adjacent and antagonist teeth
* poor periodontal status
* adverse medical history
* potential behavioral problems
Unilateral vs. Bilateral Approaches to Hybrid Stroke Rehabilitation

The aim of the project is to compare the effects of unilateral hybrid therapy \[unilateral robot-assisted therapy (RT)\] + unilateral arm training (UAT)\] and bilateral hybrid therapy \[bilateral RT + bilateral arm training (BAT)\] on motor function, daily function, mobility, life quality, and motor control strategy in stroke patients.


Eligibility Criteria:
Inclusion Criteria:

1. ≥3 months onset from a first-ever unilateral stroke;
2. minimal motor criteria to receive CIT (i.e., ≥10º wrist extension and ≥ 10º extension at the thumb and any two other digits);
3. an initial FMA-UE score of 10 to 56, indicating mild to moderate and moderate to severe upper extremity motor impairment;
4. no excessive spasticity in any of the joints of the affected arm (shoulder, elbow, wrist, and fingers);
5. able to follow instructions and perform the study tasks (Mini Mental State Examination ≥ 22);
6. without upper extremity fracture within 3 months;
7. no participation in any rehabilitation experiments or drug studies during the study period; and (8) willing to provide written informed consent.

Exclusion Criteria:

1. acute inflammatory disease;
2. major health problems or poor physical condition that might limit participation; and (3) attend any other study in recent 3 months.
Effects of Chemotherapy on the Concentration of Minerals in Hair

The purpose of the investigator's graduate student research study is to investigate if there are significant changes in hair mineral levels in cancer patients undergoing chemotherapy.

Visit 1 - Before the start of chemotherapy

* Complete a questionnaire about demographics, health, and diet.
* Weight and height will be measured.
* A small sample of the participant's hair will be collected from the back side of the head near the base of the neck. Only the hair in the first inch closest to the scalp will be included in the sample. This hair sample will weigh 0.25g to 1g, which is about the same weight as one to two regular paper clips.
* The participant will be given a food frequency questionnaire

Visit 2- Approximately 2 months after start of chemotherapy

* The participant will complete a questionnaire about their health and diet.
* weight and height will be measured
* A small sample of the participant's hair will be collected from the back side of the head near the base of the neck. Only the hair in the first inch closest to the scalp will be included in the sample. This hair sample will weigh 0.25g to 1g, which is about the same weight as one to two regular paper clips.
* The participant will be given a food frequency questionnaire.

Eligibility Criteria:
Inclusion Criteria:

* Are 18 years and older
* Recently diagnosed cancer stage 1, 2, or 3
* Assigned to receive immunosuppressive chemotherapy treatment
* Natural hair that has not been dyed or permed in the past 3 months

Exclusion Criteria:

• Prior chemotherapy treatment for cancer
Effects of Complex Training in Cricket Fast Bowlers

This study will be a randomized controlled trial and the data will be collected from National Cricket Academy and domestic cricket clubs. The sample size will be calculated by conducting a pilot study. There will be three groups. Group-A will be receiving Complex training, Group-B will be receiving Conventional training and Group C as a Control Group. Athletes with same physical fitness level will be recruited. There will be parallel assignment of the participants. Assessor will be kept blinded. All the parameters would be assessed at Baseline, 6 Weeks, 12 Weeks. Physical fitness will be assessed through Field Testing. Bowling performance will be assessed through speed machine and Kinovea Software. Work capacity will be assessed through step testing. Muscle strength will be assessed through Dynamometer. Lastly, BMD will be assessed though Bone Densitometer.

Cricket fast bowlers require a unique blend of speed, strength, power, and agility to excel in their role on the field. In recent years, Complex training has emerged as a popular training method to enhance these critical qualities among fast bowlers. Complex training involves combining strength exercises with explosive, sport-specific movements in a single training session, aiming to improve overall athletic performance. This study will be a randomized controlled trial and the data will be collected from National Cricket Academy and domestic cricket clubs. The sample size will be calculated by conducting a pilot study. There will be three groups. Group-A will be receiving Complex training, Group-B will be receiving Conventional training and Group C as a Control Group. Athletes with same physical fitness level will be recruited. There will be parallel assignment of the participants. Assessor will be kept blinded. All the parameters would be assessed at Baseline, 6 Weeks, 12 Weeks. Physical fitness will be assessed through Field Testing. Bowling performance will be assessed through speed machine and Kinovea Software. Work capacity will be assessed through step testing. Muscle strength will be assessed through Dynamometer. Lastly, BMD will be assessed though Bone Densitometer.

Eligibility Criteria:
Inclusion Criteria:

* Male bowlers between 18 - 25 years
* Bowling speed 115-130 km/h
* Same Run-up speed (20-25 km/h)
* domestic teams
* Active in game from last 6 months
* Athletes with same 1 Repetition Maximum (Bench press and Leg press)
* Athletes with same BMI category (18.5 - 24.9)

Exclusion Criteria:

* Red flags
* Resistance training from last 6 months
* Any disabling musculoskeletal injury
* Glenohumeral Internal Rotation Deficit
* Scapular Dyskinesia
* Athletes taking prohibited drugs, Ergogenic aids
* Any cardiovascular issue . Any systemic disease
Prevenar (13v) Infant Drug Use Investigation

The purpose of this study is to investigate post marketing use and safety of Prevnar ( 13v) in infants vaccinated for the first time at the age of 2 months, inclusive, to 7 months, exclusive.

The investigation will be conducted using the continuous investigation method, with which a satisfying registration conditions will be continuously registered until the number of contracted cases is reached.

Eligibility Criteria:
Inclusion Criteria:

* Vaccinees who meet all of the following conditions at the time of the first vaccination among infants who use Prevenar 13 in accordance with the indication, and dosage and administration of the vaccine will be included in the investigation:
* Infants aged 2 months, inclusive, to 7 months, exclusive
* Infants with no history of administration of pneumococcal vaccines including Prevenar 13
* Infants expected to receive 4 vaccinations

Exclusion Criteria:

* Vaccines must not be performed if the vaccinee corresponds to any of the following:
* Persons in whom a past history of anaphylaxis due to an ingredient of Prevenar 13 or diphtheria toxoid is evident
* Persons with evident pyrexia
* Persons who evidently have serious acute diseases
* Besides the persons listed above, persons who are in a status inappropriate for immunization
Subthreshold Laser Treatment for Reticular Pseudodrusen and Geographic Atrophy Secondary to AMD

To evaluate the effectiveness of subthreshold laser treatment on retinal sensitivity in patients with reticular pseudodrusen and incipient Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD). Secondary objective is to investigate changes in best-corrected visual acuity, atrophy progression and safety.


Eligibility Criteria:
Inclusion Criteria:

* GA \< 0.5 disk areas secondary to AMD and/or Reticular pseudodrusen
* 50 years or older
* The periphery of the atrophic lesions must demonstrate increased autofluorescence
* Best corrected visual acuity between 20/20 and 20/400 inclusive
* Clear ocular media
* Ability to provide informed consent and attend all study visits

Exclusion Criteria:

* GA secondary to other causes aside from AMD
* Evidence of choroidal neovascularization in either eye
* Any prior treatment for AMD, aside from antioxidants
* Any other ocular condition that would progress in the study period and confound visual acuity assessment
* Any ocular or systemic medication known to be toxic to the lens, retina or optic nerve
* Presence of idiopathic or autoimmune-associated uveitis
* Any intraocular surgery 3 months of entry
* Any prior thermal laser in the macula
* History of vitrectomy, filtering surgery, corneal transplant or retinal detachment surgery
* Previous therapeutic radiation in the ocular region in either eye
* Any treatment with an investigational agent in the previous 60 days before study entry
* Women of child-bearing potential, defined as all women less than 1 year postmenopausal or less than 6 weeks since sterilization at Baseline, unless they are using highly effective methods of contraception during dosing of study treatment
* Participation in an investigational drug, biologic, or device study within 6 Months prior to Baseline \[Note: observational clinical studies solely involving over-the-counter vitamins, supplements, or diets are not exclusionary
Comparison Between Levosimendan and Adrenaline in CABG Patients

The aim of this study is to compare between levosimendan and adrenaline in patients with pre-existing impaired systolic function (EF 30-40%), undergoing elective on-pump CABG, as regards hemodynamics and echocardiographic parameters.

Patients undergoing cardiac surgery are at risk of post-cardiotomy myocardial dysfunction. This condition causes delayed recovery, organ failure, prolonged intensive care unit and hospital stays, and an increased risk of mortality. These patients often require inotropic support, which has been associated with an increased risk of cardiovascular complications. Treatment of myocardial dysfunction includes optimization of myocardial contractility through appropriate fluid and pharmacologic management and mechanical support . Extensive use of inotropes in this situation is needed, but the optimal pharmacologic management of myocardial dysfunction in cardiac surgery is a matter of ongoing debate .Available inotropes including adrenaline may increase myocardial oxygen consumption, heart rate and risk of arrhythmia. An increase in myocardial oxygen consumption by inotropes in a state of inadequate oxygen delivery may further deteriorate underlying cardiac dysfunction and even lead to increased mortality . There are questions regarding the ideal inotrope to use during the post cardiopulmonary bypass (CPB) period in patients undergoing on-pump CABG surgery. The occurrence of myocardial dysfunction after cardiac surgery is a potential indication for the use of levosimendan, a calcium sensitizer with a unique mechanism of action. By binding to cardiac troponin C, it enhances myofilament responsiveness to calcium, thereby increasing myocardial contraction without increasing myocardial oxygen consumption. In addition, levosimendan activates adenosine triphosphate-dependent potassium channels, which are important mediators of ischemic and anesthetic cardioprotection. Levosimendan might thus have a potential benefit for patients with myocardial oxygen imbalance requiring inotropic drug support . The hypothesis of the present study is that levosimendan without loading dose can improve myocardial function and provide better hemodynamics as well as echocardiographic parameters compared with adrenaline in patients with low ejection fraction undergoing op-pump CABG

Eligibility Criteria:
Inclusion Criteria:

* ischemic hear disease
* age 18 and 65 years
* low left ventricular function (ejection fraction 30 - 40%),
* elective coronary artery bypass grafting (CABG) surgery

Exclusion Criteria:

* Age over 65 years
* Patients with end organ failure (renal, liver)
* Associated significant valve lesions
* Uncontrolled diabetes mellitus
* Emergency surgery
Patient Assessment of Topical Anesthetic Effectiveness for Intravitreal Injections

There are currently several different commercially available topical eye drops and gels used to reduce eye discomfort (topical anesthetics) during and after eye injections. Dr. Pollack is performing a research study to evaluate three commercially available topical anesthetics (eye numbing treatments) to determine if individuals have a preference for one over the other. The three topical anesthetics being studied are 1) 0.5% proparacaine hydrochloride (generic, Akorn, Inc), 2) 0.5% proparacaine hydrochloride (generic, Akorn, Inc) PLUS 4% lidocaine hydrochloride topical solution (generic, Roxane Laboratories), and 3) 3.5% lidocaine hydrochloride ophthalmic gel (Akten, Akorn, Inc). These eye anesthetics are NOT experimental medications. They are all commercially available topical anesthetics currently used in our offices and their use is widespread among retina specialists throughout the United States. Dr. Pollack will randomly select one topical anesthetic to use and he will ask you to grade your level of pain associated with the injection procedure. Answering these questions should take less than one minute of your time and your identity will NOT be revealed with the results of this study. The results of this study will be used to inform doctors which eye anesthetics patients find most effective for pain control during eye injections.

In this prospective study, 120 sequential patients undergoing 30 and 33 Gauge intravitreal injections were randomly assigned to receive either: proparacaine HCL 0.5% (Group 1), proparacaine HCL 0.5% + 4% lidocaine liquid drops (Group 2); or 3.5% lidocaine gel (Group 3) as topical anesthetic prior to injection. All procedures utilized a lid speculum and 5% povidone iodine. Approximately 10 seconds after injection, patients graded pain associated with the lid speculum, the needle, and with burning sensation on a pain scale of 0 to 10, with 0 representing no pain and 10 representing the patient's worst imaginable pain. They also graded their overall injection procedure experience as Excellent, Very Good, Fair, Poor, or Awful.

Eligibility Criteria:
Inclusion Criteria:

* Patients requiring intravitreal injection for treatment of eye disease

Exclusion Criteria:

* Eye infection
* Retinal detachment
* Age less than 18 years
* Pregnant
* Unable or unwilling to provide informed consent
Lymphocyte to Procalcitonin Ratio in Covid-19 Patients

The lymphocyte/CRP ratio has been studied many times in covid-19 patients and has been proven to be an indicator of mortality as well as poor prognosis. In this study, the role of the lymphocyte/procalcitonin ratio in predicting the hospitalization status of patients, detection of findings on CT, need for mechanical ventilation, mortality and survival is aimed to be determined. The lymphocyte/procalcitonin ratio was found to be the strongest predictor of mortality and poor prognosis, especially in patients over 65 years of age.

The lymphocyte/CRP ratio has been studied many times in covid-19 patients and has been proven to be an indicator of mortality as well as poor prognosis. In this study, the role of the lymphocyte/procalcitonin ratio in predicting the hospitalization status of patients, detection of findings on CT, need for mechanical ventilation, mortality and survival is aimed to be determined. The lymphocyte/procalcitonin ratio was found to be the strongest predictor of mortality and poor prognosis, especially in patients over 65 years of age. The auc value, PPV and specificity of the lymphocyte/procalcitonin ratio were higher than the lymphocyte/CRP ratio.

Eligibility Criteria:
Inclusion Criteria:

* Covid19 PCR test positive

Exclusion Criteria:

* Pregnancy Under 18 years old
Donor Human Milk in Young Children Receiving Bone Marrow Transplantation

The investigators hypothesize that children receiving human milk will maintain a greater diversity of helpful bacteria in their gut and have lower levels of inflammatory proteins in the blood compared with children not receiving human milk.

The investigators hypothesize that the gut microbiota during bone marrow transplant could be influenced by administration of enteral donor breast milk. This study will attempt to address this hypothesis, by feeding donor breast milk to young children undergoing transplant, and serially comparing the gut microbiota in children receiving human milk, with those receiving conventional feeding.

Eligibility Criteria:
Inclusion Criteria:

* Children less than 5 years old receiving transplant (autologous or allogeneic)
* Parents must give informed consent

Exclusion Criteria:

* Failure to meet inclusion criteria
Acute Neurocardiogenic Injury After Subarachnoid Hemorrhage.

The aim of this study is to describe acute neurocardiogenic injury after subarachnoid hemorrhage assessed with cardiac 123I-MIBG scintigraphy and 18F-FDG PET/CT during the first week and the first six months after SAH.

The study hypothesis is that the evolution of the cardiac disturbances follows the clinical evolution.

The cardiac metabolic disturbance are assessed by a 18F-FDG PET/CT in the first week after SAH and monthly until normal result.

The myocardial sympathetic innervation is assessed by a cardiac 123I-MIBG scintigraphy in the first week after SAH and six months later.

Clinical outcome is assessed by Glasgow Outcome Scale, modified Rankin Scale and MOS-SF36 at 1, 3 and 6 months after SAH.

Eligibility Criteria:
Inclusion Criteria:

* age
* SAH
* Hospitalization in the Military Teaching Hospital Sainte Anne

Exclusion Criteria:

* Refusal of consent